ObsEva (NASDAQ:OBSV) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman’s reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. “
A number of other equities analysts have also recently commented on the company. HC Wainwright set a $25.00 target price on ObsEva and gave the company a “buy” rating in a report on Thursday, December 14th. BMO Capital Markets assumed coverage on ObsEva in a report on Monday, December 4th. They set an “outperform” rating and a $20.00 target price for the company. Royal Bank of Canada restated a “buy” rating and set a $22.00 target price on shares of ObsEva in a report on Thursday, November 2nd. Finally, Credit Suisse Group assumed coverage on ObsEva in a report on Monday, October 9th. They set an “outperform” rating and a $16.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $19.00.
ObsEva (NASDAQ:OBSV) last announced its earnings results on Tuesday, November 14th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.01). The business’s revenue was up NaN% on a year-over-year basis. analysts forecast that ObsEva will post -2.26 EPS for the current year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Iguana Healthcare Management LLC boosted its stake in shares of ObsEva by 66.7% in the 3rd quarter. Iguana Healthcare Management LLC now owns 50,000 shares of the company’s stock valued at $407,000 after buying an additional 20,000 shares during the period. VHCP Management II LLC purchased a new position in shares of ObsEva in the 2nd quarter valued at about $1,283,000. Sectoral Asset Management Inc boosted its stake in shares of ObsEva by 181.9% in the 2nd quarter. Sectoral Asset Management Inc now owns 212,831 shares of the company’s stock valued at $1,820,000 after buying an additional 137,331 shares during the period. Sphera Funds Management LTD. boosted its stake in shares of ObsEva by 9.7% in the 2nd quarter. Sphera Funds Management LTD. now owns 231,497 shares of the company’s stock valued at $1,979,000 after buying an additional 20,411 shares during the period. Finally, Abingworth LLP purchased a new position in shares of ObsEva in the 3rd quarter valued at about $3,480,000. Institutional investors and hedge funds own 35.91% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://sportsperspectives.com/2017/12/21/obseva-obsv-rating-lowered-to-hold-at-zacks-investment-research.html.
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea.
Receive News & Ratings for ObsEva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ObsEva and related companies with MarketBeat.com's FREE daily email newsletter.